Vertex Pharmaceuticals price target raised to $467 from $435 at Barclays
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The ...
Vertex options imply 4.1% move in share price post-earnings
Pre-earnings options volume in Vertex is normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near ...
Yahoo Finance4d
Vertex Pharmaceuticals Incorporated (VRTX)
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...
pharmaphorum2d
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
Reuters3d
Formula 1
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
FIA Formula E6d
Cars and tech subheading
Formula E is set to get a lot faster with the introduction of the GEN3 Evo, the quickest accelerating FIA single-seater race car – Capable of 0-60mph in 1.82 seconds (0-100kph in 1.86s). Set to race ...
Racer1d
Formula 1
Unbeknownst to most of us, this time last year was an extremely stressful period for Williams. Its car was late, and significantly (…) ...